CDXS - Wutah pendapatan YoY sajrone 12 wulan kepungkur Codexis

The primary driver for Codexis, Inc. (CDXS) is the synergy between its AI platform and elite biochemists. The YoY sales growth over the last four quarters visualizes this potential, where the value of 66.90 characterizes this level. The company's pricing power is based on proprietary enzymes, while cost optimization and a shift toward licensing under revamped management create the foundation for future growth.

This indicator measures the percentage change in revenue over the last twelve months relative to the same period last year, neutralizing seasonality to determine a sustainable vector of operational expansion. By analyzing the current year-over-year (TTM) sales dynamics, an investor assesses the effectiveness of Codexis, Inc. (CDXS) diversification across the biopharmaceutical and environmental segments through the commercialization rates of innovative enzyme products.